Safety and immunogenicity of 15-valent pneumococcal conjugate vaccine compared to 13-valent pneumococcal conjugate vaccine in adults ≥65 years of age previously vaccinated with 23-valent pneumococcal polysaccharide vaccine

Safety and immunogenicity of 15-valent pneumococcal conjugate vaccine in pneumococcal vaccine-naïve adults ≥50 years of age

(2018) Susan J. Ermlich et al.   VACCINE

Risk stacking of pneumococcal vaccination indications increases mortality in unvaccinated adults with Streptococcus pneumoniae infections

(2017) Jacob B. Morton et al.   VACCINE

Repeat pneumococcal polysaccharide vaccine in Indigenous Australian adults is associated with decreased immune responsiveness

(2017) Sarah Moberley et al.   VACCINE

Risk of underlying chronic medical conditions for invasive pneumococcal disease in adults

(2016) Roger Baxter et al.   VACCINE

Multicenter Surveillance of Streptococcus pneumoniae Isolates From Middle Ear and Mastoid Cultures in the 13-Valent Pneumococcal Conjugate Vaccine Era

(2015) S. L. Kaplan et al.   CLINICAL INFECTIOUS DISEASES

Impact of infant 13-valent pneumococcal conjugate vaccine on serotypes in adult pneumonia

(2015) Chamira Rodrigo et al.   EUROPEAN RESPIRATORY JOURNAL

Redefining risk categories for pneumococcal disease in adults: critical analysis of the evidence

(2015) Daniel Curcio et al.   INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES

Effect of the 13-valent pneumococcal conjugate vaccine on invasive pneumococcal disease in England and Wales 4 years after its introduction: an observational cohort study

(2015) Pauline A Waight et al.   LANCET INFECTIOUS DISEASES

Effect of use of 13-valent pneumococcal conjugate vaccine in children on invasive pneumococcal disease in children and adults in the USA: analysis of multisite, population-based surveillance

(2015) Matthew R Moore et al.   LANCET INFECTIOUS DISEASES

Safety, Tolerability and Immunogenicity of 15-valent Pneumococcal Conjugate Vaccine in Toddlers Previously Vaccinated With 7-valent Pneumococcal Conjugate Vaccine

(2015) Ajoke Sobanjo-ter Meulen et al.   PEDIATRIC INFECTIOUS DISEASE JOURNAL

Decline in Pneumococcal Nasopharyngeal Carriage of Vaccine Serotypes After the Introduction of the 13-Valent Pneumococcal Conjugate Vaccine in Children in Atlanta, Georgia

(2015) Ankita P. Desai et al.   PEDIATRIC INFECTIOUS DISEASE JOURNAL

Intervals Between PCV13 and PPSV23 Vaccines: Recommendations of the Advisory Committee on Immunization Practices (ACIP)

(2015) Miwako Kobayashi et al.   MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT

Changes in Pneumococcal Serotypes and Antimicrobial Resistance after Introduction of the 13-Valent Conjugate Vaccine in the United States

(2014) Sandra S. Richter et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Early Impact of 13-Valent Pneumococcal Conjugate Vaccine on Community-Acquired Pneumonia in Children

(2014) F. Angoulvant et al.   CLINICAL INFECTIOUS DISEASES

Sequential administration of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine in pneumococcal vaccine–naïve adults 60–64 years of age

(2014) Richard N. Greenberg et al.   VACCINE

Effect of 13-valent pneumococcal conjugate vaccine on admissions to hospital 2 years after its introduction in the USA: a time series analysis

(2014) Lone Simonsen et al.   Lancet Respiratory Medicine

Serotype distribution of invasive Streptococcus pneumoniae in Canada after the introduction of the 13-valent pneumococcal conjugate vaccine, 2010–2012

(2013) Walter H.B. Demczuk et al.   CANADIAN JOURNAL OF MICROBIOLOGY

U.S. Hospitalizations for Pneumonia after a Decade of Pneumococcal Vaccination

(2013) Marie R. Griffin et al.   NEW ENGLAND JOURNAL OF MEDICINE

Influence of initial vaccination with 13-valent pneumococcal conjugate vaccine or 23-valent pneumococcal polysaccharide vaccine on anti-pneumococcal responses following subsequent pneumococcal vaccination in adults 50 years and older

(2013) Lisa A. Jackson et al.   VACCINE

Immunogenicity and safety of a 13-valent pneumococcal conjugate vaccine in adults 70 years of age and older previously vaccinated with 23-valent pneumococcal polysaccharide vaccine

(2013) Lisa A. Jackson et al.   VACCINE

Decreased immune response to pneumococcal conjugate vaccine after 23-valent pneumococcal polysaccharide vaccine in children

(2013) Sigurveig Th. Sigurdardottir et al.   VACCINE

Healthcare utilization and cost of pneumococcal disease in the United States

(2011) Susan S. Huang et al.   VACCINE

Hyporesponsiveness to re-challenge dose following pneumococcal polysaccharide vaccine at 12 months of age, a randomized controlled trial

(2010) F.M. Russell et al.   VACCINE

Serotype specific invasive capacity and persistent reduction in invasive pneumococcal disease

(2010) Inci Yildirim et al.   VACCINE

Immunogenicity and Reactogenicity of Pneumococcal Polysaccharide and Conjugate Vaccines in Alaska Native Adults 55–70 Years of Age

(2009) Karen M. Miernyk et al.   CLINICAL INFECTIOUS DISEASES

Sustained Reductions in Invasive Pneumococcal Disease in the Era of Conjugate Vaccine

(2009) Tamara Pilishvili et al.   JOURNAL OF INFECTIOUS DISEASES